Efficacy of cefepime and amikacin in the empiric treatment of febrile neutropenic children with cancer.
Chastagner
P
P
Pediatric Oncology Department, CHU Nancy, Nancy, France. p.chastagner@chu-nancy.fr
Plouvier
E
E
Eyer
D
D
Plesiat
P
P
Lozniewski
A
A
Sommelet
D
D
D000293:Adolescent; D000583:Amikacin / Q000008:administration & dosage / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy; D000077723:Cefepime; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D005334:Fever / Q000188:drug therapy*; D005335:Fever of Unknown Origin / Q000188:drug therapy; D006801:Humans; D007223:Infant; D008297:Male; D009369:Neoplasms / Q000150:complications*; D009503:Neutropenia / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000077723:Cefepime; D000583:Amikacin